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Abstract
Objective: A minority of HIV-1 positive individuals treated with antiretroviral therapy (ART) in primary HIV-1 infection
(PHI) maintain viral suppression on stopping. Whether this is related to ART duration has not been explored.
Design: And Methods: Using SPARTAC trial data from individuals recruited within 6 months of seroconversion, we
present an observational analysis investigating whether duration of ART was associated with post-treatment viraemic
control. Kaplan-Meier estimates, logistic regression and Cox models were used.
Results: 165 participants reached plasma viral loads (VL) <400 copies/ml at the time of stopping therapy (ART stop).
After ART stop, 159 experienced confirmed VL ≥400 copies/ml during median (IQR) follow-up of 167 (108,199)
weeks.
Most participants experienced VL rebound within 12 weeks from ART stop, however, there was a suggestion of a
higher probability of remaining <400 copies/ml for those on ART >12 weeks compared to ≤12 weeks (p=0.061).
Cumulative probabilities of remaining <400 copies/ml at 12, 52 and 104 weeks after ART stop were 21%
(95%CI=13,30), 4% (1,9), and 4% (1,9) for ≤12 weeks ART, and 32% (22,42), 14% (7,22), and 5% (2,11) for >12
weeks.
In multivariable regression, ART for >12 weeks was independently associated with a lower probability of being
≥400 copies/ml within 12 weeks of ART stop (OR=0.11 (95%CI=0.03,0.34), p<0.001)). In Cox models of time to VL
≥400 after 12 weeks, we only found an association with female sex (OR=0.2, p=0.001).
Conclusion: Longer ART duration in PHI was associated with a higher probability of viral control after ART stop.
Trial Registration: Controlled-Trials.com 76742797 http://www.controlled-trials.com/ISRCTN76742797.
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Introduction
Antiretroviral therapy (ART) suppresses viral replication to
undetectable levels, but is unlikely to confer complete viral
eradication [1,2]. Examples of HIV-1 positive individuals treated
in primary HIV-1 infection (PHI) who maintain viral suppression
when ART is stopped have received much attention as the
mechanisms behind ‘post-treatment control’ (PTC) might inform
strategies for achieving drug-free remission [3-5].
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The timing and duration of therapy required to induce PTC is
unclear, as are host and viral factors that may contribute. The
SPARTAC (Short Pulse ART at Seroconversion) trial is the
largest international randomised study of short-course therapy
in PHI [6]. We present an analysis of the trial data investigating
whether either 12 or 48 weeks of ART commenced within six
months of the estimated date of seroconversion was
associated with post-treatment viraemic control on cessation of
therapy.
Methods
The SPARTAC trial
The protocol for the SPARTAC trial is available as supporting
information; see Protocol S1. The supporting CONSORT
checklist is published elsewhere [6]
Ethics Statement
The SPARTAC trial was approved by the following
authorities: Medicines and Healthcare products Regulatory
Agency (UK), Ministry of Health (Brazil), Irish Medicines Board
(Ireland), Medicines Control Council (South Africa), and The
Uganda National Council for Science and Technology
(Uganda). It was also approved by the following ethics
committees in the participating countries: Central London
Research Ethics Committee (UK), Hospital Universitário
Clementino Fraga Filho Ethics in Research Committee (Brazil),
Clinical Research and Ethics Committee of Hospital Clinic in
the province of Barcelona, Spain, The Adelaide and Meath
Hospital Research Ethics Committee (Ireland), University of
Witwatersrand Human Research Ethics Committee, University
of Kwazulu-Natal Research Ethics Committee and University of
Cape Town Research Ethics Committee (South Africa),
Uganda Virus Research Institute Science and ethics committee
(Uganda), The Prince Charles Hospital Human Research
Ethics Committee and St Vincent's Hospital Human Research
Ethics Committee (Australia), and the National Institute for
Infectious Diseases Lazzaro Spallanzani, Institute Hospital and
the Medical Research Ethics Committee, and the ethical
committee Of the Central Foundation of San Raffaele,
MonteTabor (Italy). All participants signed a written informed
consent.
Patients and statistical analyses
366 adults were randomized within six months of the
estimated date of HIV-1 seroconversion to receive ART for 48
weeks (ART-48, n=123), 12 weeks (ART 12, n=120) or none
(Standard Care, n=123). The criteria for diagnosing PHI are
described elsewhere [6].
For participants randomised to either the ART 12 or ART 48
trial arms, we included data from those with both an HIV-1 RNA
measurement available within 14 days prior to stopping ART
and at least one subsequently, and who had plasma viral loads
<400 copies/ml at the time of stopping. We estimated time to
viral rebound (≥400 copies/ml) using time-to-event methods,
censoring at time last seen or on starting long-term ART. We
assessed whether the probability of maintaining an
undetectable viral load <400 copies/ml following ART stop was
associated with ART duration using a log-rank test and a 12-
week cut-off to differentiate between two ART groups.
Analyses were undertaken using actual duration of therapy
rather than according to trial randomisation.
To explore virological control in participants who did not
receive ART in PHI, we analysed data from those who never
commenced therapy and with documented HIV-1 plasma viral
load measurements available at recruitment and then
subsequently.
‘Log-log’ plots (data not shown) showed that the hazards in
the two ART groups (≤12 or >12 weeks) were not proportional
over the whole analysis time, so we used logistic regression to
first examine the effect of the duration of therapy on HIV-1 RNA
rebound by 12 weeks after stopping ART. We adjusted for sex,
site (African vs non-African), age, baseline RNA, baseline CD4,
and interval between estimated seroconversion and ART
initiation. We then used Cox proportional hazard models to
examine this effect on time to RNA ≥400 copies/ml after 12
weeks from ART stop for those remaining undetectable. We
repeated the analyses restricted to data from the subset of
individuals at (non-African) sites where HIV-1 RNA assays with
detection limits < 50 copies/ml were used.
Results
Patient Selection and Demographics
Of 243 participants in SPARTAC randomised to receive
ART, 5 did not start ART, and 5 started but did not stop ART.
Of the 233 remaining, 39 had no HIV-1 RNA measurement
available at the time of stopping ART. Of the 194 with available
plasma HIV-1 RNA data, 165 (85%) reached <400 copies/ml at
the time of ART cessation (86 and 79, for ART 12 and ART 48,
respectively). The actual duration of ART received was a
median (IQR, range) of 12 (12 to 12, 11 to 16) and 48 (48 to
48, 12 to 53) weeks for ART 12 and ART 48, respectively. The
majority (n=110) were male, most of whom were infected
through sex between men (n=101). At randomisation, the
median (IQR) age was 34 (27 to 41) years, the estimated time
since seroconversion was 85 (IQR, 60 to 101) days, the CD4
cell count was 565 (IQR, 463 to 707) cells/mm3 and the log10
HIV-1 RNA was 4.39 (IQR, 3.66 to 5.04) copies/ml of plasma
(Table 1). Fourteen (8%) of the 165 participants had HIV-1
RNA ≤400 copies/ml at randomisation, before ART initiation.
Analysis of ‘post treatment control’ in SPARTAC
On stopping ART, 159 of the 165 participants experienced a
confirmed viral load rebound ≥400 RNA copies/ml (i.e. on two
consecutive occasions) during a median (IQR) follow-up of 167
(108 to 199) weeks, censored at the time of commencing long-
term ART. A further two participants had one HIV-1 RNA
measurement ≥400 copies/ml within one month of stopping
ART, followed by initiation of long-term ART or loss to follow-
up. The remaining four participants (1 ART 12, 3 ART 48)
remained <400 copies/ml for 164-202 weeks, three of whom
experienced one to four HIV-1 RNA blips ≥400 copies/ml. The
pre-therapy baseline viral loads for these 4 individuals were:
13,000 and 18,600 copies/ml for one, 1090 and 459 copies/ml
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for the second, <400 copies/ml for the third, and <100
copies/ml for the fourth (ART 12 recipient). The CD4 cell
counts on stopping ART for these participants were between
769-1429 cells/mm3.
Analysis of time to plasma viral load rebound
The majority of participants experienced an HIV-1 plasma
RNA rebound within 12 weeks from stopping ART, with overall
Kaplan-Meier estimates for the probability of remaining <400
copies/ml at 12, 52 and 104 weeks of 26% (95% CI, 20 to 33),
9% (95% CI, 5 to 14) and 4% (95% CI, 2 to 8), respectively.
Comparing participants who received >12 weeks of ART
compared with ≤12 weeks revealed a statistically non-
significant higher probability of remaining <400 copies/ml after
stopping therapy for those on ART for >12 weeks (p=0.061).
Cumulative probabilities of remaining <400 copies/ml at 12, 52
and 104 weeks after stopping ART were estimated to be 32%
(95% CI, 22 to 42), 14% (95% CI, 7 to 22), and 5% (95% CI, 2
to 11) for those prescribed >12 weeks ART, compared with
21% (95% CI, 13 to 30), 4% (95% CI, 1 to 9), and 4% (95% CI,
1 to 9) for those receiving ≤12 weeks ART (Figure 1a).
When exploring the probability of viral load rebound within
the first 12 weeks after stopping therapy, we found strong
evidence that taking ART for >12 weeks was independently
associated with maintaining <400 copies/ml (Odds Ratio 0.11
(95% CI, 0.03 to 0.34), p<0.001), as was female sex (Odds
Ratio 0.28 compared to men (95% CI, 0.10 to 0.80), p=0.017).
Higher baseline HIV-1 viral load prior to starting ART was
associated with a higher probability of viral rebound to ≥400
RNA copies/ml (4.08 per one log10 increase (2.32 to 7.17),
p<0.001). There was no evidence that having HIV-1 RNA ≥400
copies/ml after stopping ART was associated with the interval
between estimated time since seroconversion and ART
initiation (p=0.25), age (p=0.74), or CD4 cell count at
randomisation (p=0.36).
In univariable and multivariable (all covariates as in previous
models except for sex) analyses, participants from African sites
also had a lower probability of HIV-1 RNA ≥400 copies/ml
during the first 12 weeks after stopping ART, however, as all
African participants were female this effect could not be
disentangled from that of sex. In sensitivity analyses, the effect
of ART duration remained practically unchanged when African
participants were excluded (OR 0.08 (95%CI, 0.01 to 0.44),
p=0.004) or those with HIV-1 RNA <400 copies/ml at
randomisation (i.e. before start of ART), or whether we
included a factor in the model for having HIV-1 RNA <400
copies/ml at randomisation (data not shown).
In Cox models exploring determinants for viral rebound more
than 12 weeks after stopping therapy (in those who were <400
copies/ml at 12 weeks), we only found an association with sex
(Hazard Ratio 0.2 compared to men (95%CI, 0.1 to 0.5),
p=0.001), but not with duration of ART, baseline HIV-1 RNA or
any other factor.
Restricting analyses to the subset of participants (n=126)
recruited at centres using an HIV-1 RNA assay with a detection
Table 1. Baseline characteristics for participants in SPARTAC analysed in this study.
Baseline variable  
Participants who did
not start ART
Participants who
started and stopped
ART*
Overall study
population
Study population: ART
≤12 weeks
Study population: ART
>12 weeks
  (n=127) (n=233) (n=165) (n=86) (n=79)
Randomised arm: no ART 122 (96%) ♯ 0 0 0 0
 ART 12 0 120 (52%) 86 (52%) 85 (99%) 1 (1%)
 ART 48 5 (4%) 113 (49%) 79 (48%) 1 (1%) 78 (99%)
Sex: Male 74 (58%) 139 (60%) 110 (67%) 52 (60%) 58 (73%)
 Female 53 (42%) 94 (40%) 55 (33%) 34 (40%) 21 (27%)
Site: Africa 49 (39%) 88 (38%) 49 (30%) 31 (36%) 18 (23%)
 Other 78 (61%) 145 (62%) 116 (70%) 55 (64%) 61 (77%)
Risk group: MSM+ 72 (57%) 127 (55%) 101 (61%) 48 (56%) 53 (67%)
 Heterosexual 54 (43%) 104 (45%) 62 (38%) 37 (43%) 25 (32%)
 Other / unknown 1 (1%) 2 (1%) 2 (1%) 1 (1%) 1 (1%)
Age (years) 31 (25-38) 32 (24-40) 34 (27-41) 33 (26-40) 34 (28-43)
Time from estimated
seroconversion to
randomisation
(days) 79 (58-103) 85 (63-106) 85 (60-101) 82 (63-100) 86 (57-102)
CD4 (cells/mm3) 557 (413-724) 560 (445-700) 565 (463-707) 543 (464-670) 600 (455-735)
Log10 HIV-1-RNA (copies/mL) 4.68 (3.68-5.24) 4.42 (3.66-5.13) 4.39 (3.66-5.04) 4.24 (3.49-4.68) 4.66 (3.96-5.24)
Values are number (%) or, for continuous variables, median (interquartile range).
*. Includes patients randomised to either the ART 12 and ART 48 arms. Of the 243 participants recruited to receive ART, 5 never started (and are included in the untreated
analysis detailed in the first column) and 5 started but never stopped, and have been excluded from the analysis.
♯. Of 123 participants in the Standard Care arm, 1 did not have baseline RNA measurements available and was excluded.
+. Men who have sex with men.
doi: 10.1371/journal.pone.0078287.t001
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threshold of 50 copies/ml, 88 (70%) achieved a plasma HIV-1
RNA <50 copies/ml. One participant had HIV-1 RNA <50
copies/ml at randomisation. For these 88 participants (Figure
1b), HIV-1 RNA rebound occurred much sooner, and only 14%
of participants (95% CI, 7 to 22) remained <50 copies/ml at 12
weeks, and none beyond 52 weeks after ART stop. Cumulative
probabilities of remaining <50 copies/ml at 12 weeks after ART
stop were 9% (95% CI, 2 to 21) and 17% (95% CI, 8 to 28) for
those treated for ≤12 weeks and >12 weeks, respectively
(p=0.31) (Figure 1b). Multivariable logistic regression of having
confirmed HIV-1 RNA ≥50 copies/ml during the first 12 weeks
from ART stop showed trends similar to the analysis using the
400 copies/ml threshold for the effect of ART duration (p=0.13)
and HIV-1 RNA at randomisation (p=0.08).
Figure 1.  Time to confirmed plasma HIV-1 RNA detection
by duration of ART.  Kaplan Meier survival analysis showing
time to virological rebound defined as (a.) <400 HIV-1 RNA
copies/ml of plasma and, (b.) <50 RNA copies/ml of plasma.
The x-axis shows weeks since cessation of ART. The y-axis
shows proportions of participants remaining undetectable.
Numbers at risk and contributing to the analysis at each time-
point are shown below the x-axis. ART: antiretroviral therapy;
VL = viral load.
doi: 10.1371/journal.pone.0078287.g001
Of the 127 who did not initiate ART and had HIV-1 RNA
measurements available at baseline and subsequently (122
randomised to no therapy and 5 who had been, but did not
initiate it), 11 had plasma viral loads <400 copies/ml at
randomisation, one of whom did not experience confirmed
HIV-1 RNA rebound during nearly 4 years of follow-up,
although experiencing 2 blips in the first year. The remaining
10 participants all experienced confirmed HIV-1 RNA ≥ 400
copies/ml within the 1st (n=5), 2nd (n=1), 3rd (n=1), and 4th (n=3)
year of follow-up, respectively (median 96 weeks). Three
participants who did not initiate ART and had detectable
viraemia (HIV-1 RNA ≥400 copies/ml) at baseline achieved a
viral load <400 copies/ml within 12 months; two rebounded
after 4 and 99 weeks, and the other remained <400 copies for
233 weeks.
Discussion
We analysed data from participants enrolled in SPARTAC
sampled out to a median of 167 weeks, showing that the
majority (98%) had rebound viraemia on cessation of ART -
only four participants maintained HIV-1 RNA <400 copies/ml on
stopping therapy. Given their low pre-therapy baseline viral
loads, it is possible that they may have controlled
spontaneously, making it difficult to distinguish between the two
phenotypes (i.e. spontaneous control vs PTC) [7]. This would
be consistent with the finding that 3% of untreated participants
in SPARTAC spontaneously controlled viral replication in the
first 3 years following seroconversion (4 of 127). Other studies
have also reported spontaneously controlled viraemia in
3.7-6.7% of untreated individuals [7-10].
We did not identify individuals with prolonged viral
suppression after therapy equivalent in number to those
described elsewhere [3,11]. However, we find evidence for an
independent association between the duration of treatment in
PHI and the likelihood of viral load rebound. Our data suggest
that spontaneous treatment-independent suppression alone
cannot explain these findings, which is supported by recent
findings from the VISCONTI study which suggest that PTCs
and spontaneous controllers are likely to be two separate
phenotypes [11]. Although other cohorts have reported results
suggestive of PTC [12], none of these studies found evidence
of a treatment duration effect on the probability of PTC.
Our data from SPARTAC are consistent with a transient
effect of ART in PHI on viral suppression on stopping therapy.
14% of participants were <400 copies/ml at 52 weeks if they
had received 12 or more weeks of ART in PHI, a higher
proportion than those receiving less than 12 weeks. Our study
is limited by the fact that the maximum treatment duration
before stopping was 53 weeks. It may, therefore, be possible to
achieve higher proportions (or even sustained control) with a
longer ART duration.
The impact of therapy at PHI on subsequent viraemia and
clinical progression remains a clinically and mechanistically
important question. SPARTAC demonstrated clinical benefit
and suppression of viraemia with 48 (but not 12) weeks of
short-course ART, and the analyses presented here
demonstrate that time on therapy is associated with the
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duration of viral suppression on stopping. With a median follow
up of 167 weeks, we find no convincing evidence from our
dataset of sustained PTC. Further comparison of patients from
different cohorts would benefit from agreed criteria against
which to test PTC, which would assist with discrimination from
spontaneous control. Data from the VISCONTI cohort suggest
that the mechanism of PTC is distinct from elite controllers in
that there is no enrichment for favourable HLA Class I alleles
and no evidence of strong T cell immunity [11]. The proviral
reservoir is low in both cases, and whether this is mechanistic
demands further investigation in larger studies.
Three factors in our study population were strongly
correlated with viraemic control: African site, sex and HIV RNA
threshold used (i.e. <50 versus <400 copies/ml). Of these
parameters it is not possible to discriminate between effects:
both female sex and African site were strong predictors of
remaining < 400 copies/ml for longer, however, all participants
from African sites were female, and there were only 6 women
from non-African sites.
The impact of sex has been reported previously. In the
CASCADE cohort, amongst untreated individuals with PHI,
women were more likely to achieve undetectable viraemia [10].
In the ANRS CO6 PRIMO study, women recruited at PHI were
more likely to achieve post-treatment control after ART
interruption compared with men [5]. Our findings are therefore
consistent with these other reports, however due to our study
design we cannot disentangle sex from other possible factors.
These data warrant further investigation, and consideration of
sex needs to be incorporated into future study designs, to allow
an independent effect to be determined and underlying
mechanisms explored.
Studies on the impact of site (African vs non-African), or
associated HIV-1 subtypes, can be confounded by socio-
economic or epidemiological factors, and the published
evidence for an impact on clinical progression is not strong
[13-15]. It is not surprising that using data from participants with
suppression below 50 HIV-1 RNA copies/ml was associated
with faster rebound compared with 400 RNA copies/ml. The
assay with a detection threshold of 400 copies/ml was only
used in the African sites, and therefore exclusion of these sites
removes participants with lower risk of rebound (most females
and all African participants). It is not possible to infer in this
study whether the choice of assay impacted the observed
times to rebound, but the evidence for an enhanced ‘post-
treatment control’ effect in the African participants warrants
further investigation.
In conclusion, we find a transient post-treatment effect on
viral suppression, which supports the arguments for initiating
ART in PHI. Further studies to understand the mechanisms
behind this effect will help determine whether long-term
virological remission is an achievable goal.
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